Its articles will include negative results, reproducibility studies, and peer reviewers’ names.

The university and the publisher have been trying to forge a new licensing agreement for the last year.

Scientists are working to maximize the benefits and minimize the costs of sharing.

Nine of the most recent retractions from AACR journals are for papers coauthored by embattled cancer researcher Bharat Aggarwal.

The founding editor-in-chief will redirect his focus to a Parkinson’s organization.

The Federal Trade Commission won an initial ruling against the India-based publisher for allegedly misleading researchers and for misrepresenting journal impact factors and editorial boards. 

The authors of two new studies on the payments suggest stricter guidelines are needed.

New papers from a cancer journal once named as a possibly predatory publication will no longer appear in the widely used research database.

The publisher will ask its journal editors to adopt widely accepted standards on transparency and openness in scientific communication.